{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026356","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.370767+00:00","generated_at":"2026-06-22T04:43:32.930166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxart Q3 net loss $29.3M; cash $114.8M; clinical milestones set for 2023","bullets":["Net loss $29.3M ($0.23 EPS) vs $17.6M ($0.14) Q3 2021; R&D spend rose 81% to $22.5M.","Cash & securities $114.8M at Sep 30, down from $131.5M at Jun 30; ops used $14.6M.","Phase II COVID-19 vaccine showed mucosal IgA and cross-reactivity to Omicron; UK challenge trial set for 2H 2023.","Norovirus Phase Ib in elderly (55-80) showed dose-dependent IgA; Phase II challenge data expected Q1/Q2 2023.","Added Ray Stapleton as CTO and Elaine Heron & Mark Watson to board in August 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026356","json":"https://secwatch.observer/filing/0001437749-22-026356.json","markdown":"https://secwatch.observer/filing/0001437749-22-026356.md","text":"https://secwatch.observer/filing/0001437749-22-026356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/0001437749-22-026356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/vxrt20221014_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:43:32.930166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa9bb2c54f7d1839995571baad3fe3bea342c35c","claim":"Vaxart, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Vaxart, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/0001437749-22-026356-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}